

CITATION REPORT

List of articles citing

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study

DOI: 10.1111/j.1365-2036.2006.02885.x

Alimentary Pharmacology and Therapeutics, 2006, 23, 1143-5

Source: <https://exaly.com/paper-pdf/40425833/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
347	A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. 2006 , 169, 846-60		221
346	Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. 2007 , 42, 139-47		17
345	Present and future therapeutic strategies in non-alcoholic fatty liver disease. 2007 , 11, 1231-49		39
344	Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury. 2007 , 48, 1885-96		48
343	Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. <i>American Journal of Clinical Nutrition</i> , 2007 , 86, 285-300	7	292
342	Current World Literature. 2007 , 23, 199-215		
341	Bibliography. Current world literature. Liver. 2007 , 23, 329-56		
340	Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. 2007 , 47, 711-7		391
339	Omega 3 - Omega 6: What is right for the liver?. 2007 , 47, 718-25		149
338	Quel régime en cas de stéatose hépatique non alcoolique ?. 2007 , 1, 55-56		
337	Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. 2007 , 45, 767-77		105
336	Omega-3 fatty acids and liver disease. 2007 , 45, 841-5		55
335	Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddY mice. 2007 , 46, 1779-90		37
334	Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. 2007 , 18, 184-95		211
333	Superiority of contrast echocardiography over conventional echocardiography in diagnosing left ventricular hypertrabeculation/noncompaction. 2007 , 99, 145-6		4
332	Omega-3 may indirectly reduce hepatocyte triglycerides through modulation of hyperinsulinemia, cytokines and adipocytokines. 2007 , 99, 146		2
331	[Can metabolic steatohepatitis be treated?]. 2007 , 31, 333-40		0

330	Current treatments in nonalcoholic steatohepatitis. 2007 , 10, 425-34	5
329	Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. 2008 , 47, 1513-23	129
328	Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. 2008 , 48, 670-8	148
327	Review article: diagnosis and treatment of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 503-22	6.1 84
326	Diagnosis and therapy of nonalcoholic steatohepatitis. 2008 , 134, 1682-98	277
325	Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. 2008 , 40, 194-9	209
324	Obesity, inflammation, and the potential application of pharmaconutrition. 2008 , 23, 16-34	111
323	Foods and liver health. 2008 , 29, 144-50	38
322	Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. 2008 , 48, 300-7	169
321	Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice. 2008 , 49, 441-50	85
320	Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. 2008 , 49, 821-30	310
319	Lipid accumulation in non-adipose tissue and lipotoxicity. 2008 , 94, 231-41	340
318	Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. 2008 , 2, 217-31	12
317	Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. 2008 , 60, 311-57	288
316	Treatment options for nonalcoholic Fatty liver disease. 2008 , 1, 173-89	10
315	Therapy for nonalcoholic fatty liver disease. 2008 , 42, 332-5	6
314	Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. 2008 , 11, 620-5	14
313	Nonalcoholic fatty liver disease: the potential role of nutritional management. 2008 , 11, 766-73	23

312	Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. 2008 , 42, 413-8		192
311	Dietary Supplementation With Omega-3 Polyunsaturated Fatty Acids. 2008 , 34, 1-4		1
310	Diet and nonalcoholic fatty liver disease. 2008 , 19, 25-9		22
309	Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. <i>World Journal of Gastroenterology</i> , 2008 , 14, 6395-400	5.6	151
308	Do Dietary Modifications Made Prior to Pubertal Maturation Have the Potential to Decrease Obesity Later in Life? A Developmental Perspective. 2009 , 1, 271-281		2
307	Docosahexaenoic acid enhances hepatic serum amyloid A expression via protein kinase A-dependent mechanism. 2009 , 284, 32239-47		19
306	Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. 2009 , 58, 203-8		175
305	Nonviral Hepatitis. 2009 , 22, 388-404		5
304	Review article: omega-3 fatty acids [a promising novel therapy for non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 31, 679-692	6.1	125
303	Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. 2009 , 10, 412-9		59
302	Non-alcoholic fatty liver disease from pathogenesis to management: an update. 2010 , 11, 430-45		128
301	Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. 2009 , 1792, 1080-6		157
300	Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. 2009 , 80, 229-38		52
299	Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). 2009 , 48, 1-26		471
298	Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. 2009 , 94, 3842-8		141
297	Pharmacologic therapy of non-alcoholic steatohepatitis. 2009 , 13, 667-88		24
296	Fatty acid composition and development of hepatic lipodosis during food deprivation--mustelids as a potential animal model for liver steatosis. 2009 , 234, 278-86		23
295	Effect of weight loss on nonalcoholic fatty liver disease. 2009 , 43, 970-4		31

294	Metabolic disturbances in non-alcoholic fatty liver disease. 2009 , 116, 539-64	192
293	Pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) deficiency attenuates the long-term negative effects of a high-saturated fat diet. 2009 , 423, 243-52	52
292	Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. 2009 , 250, 691-7	198
291	Current and future therapeutic strategies in NAFLD. 2010 , 16, 1958-62	6
290	Non-Alcoholic Fatty Liver Disease. 2010 , 19, 36-50	4
289	The importance of fatty liver disease in clinical practice. 2010 , 69, 518-27	13
288	Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. 2010 , 13, 709-14	52
287	Omega-3 fatty acids: a promising alternative treatment approach for patients with nonalcoholic fatty liver disease. 2010 , 55, 2422-3; author reply 2423	1
286	Liver NF- κ B and AP-1 activation and PPAR- α expression are negatively correlated in obese patients: pro-inflammatory implications. 2010 , 29, 687-8	15
285	Eicosapentaenoic acid improves hepatic steatosis independent of PPAR- α activation through inhibition of SREBP-1 maturation in mice. 2010 , 80, 1601-12	58
284	What is critical for liver surgery and partial liver transplantation: size or quality?. 2010 , 52, 715-29	84
283	Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. 2010 , 64, 968-83	32
282	Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. 2010 , 18, 937-44	120
281	Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. 2010 , 18, 1460-3	93
280	Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. 2010 , 64, 1179-85	41
279	Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 679-92	6.1 121
278	Protection against in vivo liver ischemia-reperfusion injury by n-3 long-chain polyunsaturated fatty acids in the rat. 2010 , 44, 854-63	36
277	Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. 2010 , 61, 792-802	94

276	Mechanisms and clinical implications of hepatocyte lipoapoptosis. 2010 , 5, 71-85	74
275	Nonalcoholic Fatty Liver Disease. 2010 , 1153-1179	
274	Treatment options for nonalcoholic fatty liver disease. 2010 , 3, 121-37	103
273	A position statement on NAFLD/NASH based on the EASL 2009 special conference. 2010 , 53, 372-84	726
272	Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease assessed by 3.0T MR spectroscopy. 2010 , 75, e102-7	23
271	n-3 PUFA and lipotoxicity. 2010 , 1801, 362-6	38
270	Fatty liver: role of inflammation and fatty acid nutrition. 2010 , 82, 265-71	77
269	Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. 2010 , 49, 407-19	35
268	Advances in the treatment of nonalcoholic fatty liver disease. 2010 , 1, 101-15	11
267	The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. 2011 , 2, 644-8	121
266	Thermal and refining processes, not fermentation, tend to reduce lipotropic capacity of plant-based foods. 2011 , 2, 483-504	6
265	Advances in pediatric nonalcoholic fatty liver disease. 2011 , 58, 1375-92, x	39
264	Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats. 2011 , 43, 984-90	37
263	Pharmaconutrition for the obese, critically ill patient. 2011 , 35, 60S-72S	15
262	Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. 2011 , 96, 350-3	195
261	n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice. 2011 , 1811, 491-7	24
260	Chemical composition of hepatic lipids mediates reperfusion injury of the macrosteatotic mouse liver through thromboxane A(2). 2011 , 55, 1291-9	12
259	Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease. 2011 , 85, 197-203	30

258	La stéatohépatite non alcoolique. Influence de la nutrition, de la physiopathologie au traitement. <i>Nutrition Clinique Et Metabolisme</i> , 2011 , 25, 153-163	0.8
257	Dietary omega-3 fatty acids aid in the modulation of inflammation and metabolic health. 2011 , 65, 106-111	44
256	Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition. 2011 , 9, 128-35	12
255	Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3377-89	5.6 187
254	[Not Available]. 2011 , 153 Suppl 3, 90-94	
253	Omega-3 polyunsaturated fatty acids: photoprotective macronutrients. 2011 , 20, 537-43	48
252	Lipotropic capacity of raw plant-based foods: A new index that reflects their lipotrope density profile. 2011 , 24, 895-915	10
251	The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. 2011 , 30, 6-19	89
250	Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. 2011 , 56, 1065-74	42
249	Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. 2011 , 10, 234	49
248	ASH and NASH. 2011 , 29, 202-10	59
247	Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury. 2011 , 49, 159-62	10
246	Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats. 2012 , 2012, 268680	20
245	Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. 2012 , 50, 297-303	17
244	Nutrition therapy for liver diseases based on the status of nutritional intake. 2012 , 2012, 859697	17
243	Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. 2012 , 2012, 107434	56
242	The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury. 2012 , 2012, 802384	13
241	Dyslipidemia in patients with nonalcoholic fatty liver disease. 2012 , 32, 22-9	135

240	The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. 2012 , 46, 457-67		70
239	Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. 2012 , 10, 162-72		42
238	The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. 2012 , 142, 1592-609		1208
237	Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease. 2012 , 59, 939-44		42
236	Management of nonalcoholic steatohepatitis: an evidence-based approach. 2012 , 16, 631-45		36
235	Nonalcoholic fatty liver disease: a nutritional approach. 2012 , 10, 161-6		18
234	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. 2012 , 33, 1190-200		312
233	Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. 2012 , 56, 944-51		384
232	The role of diet and nutrient composition in nonalcoholic Fatty liver disease. 2012 , 112, 401-9		114
231	Carbohydrate but not fat is associated with elevated aminotransferases. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1064-72	6.1	9
230	Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5839-47	5.6	121
229	Nonalcoholic fatty liver disease: from lipid profile to treatment. 2012 , 5, 313-21		7
228	The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 2012 , 107, 811-26		279
227	N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. <i>PLoS ONE</i> , 2012 , 7, e46400	3.7	76
226	The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 2012 , 55, 2005-23		2285
225	Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. 2012 , 57, 1773-81		49
224	Alteration of fatty acid metabolism in the liver, adipose tissue, and testis of male mice conceived through assisted reproductive technologies: fatty acid metabolism in ART mice. 2013 , 12, 5		19
223	Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. 2013 , 33, 231-48		196

222	Peroxisome Proliferator-Activated Receptors. 2013,	4
221	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. 2013, 1281, 106-22	183
220	Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. 2013, 71, 753-71	27
219	Liver disease and malnutrition. 2013, 27, 619-29	38
218	Pharmacological agents for NASH. 2013, 10, 676-85	52
217	Pharmacological agents for nonalcoholic steatohepatitis. 2013, 7 Suppl 2, 833-41	2
216	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. 2013, 28, 40-51	46
215	Effect of stearidonic acid-enriched soybean oil on fatty acid profile and metabolic parameters in lean and obese Zucker rats. 2013, 12, 147	8
214	Oils rich in linolenic acid independently protect against characteristics of fatty liver disease in the Δ -desaturase null mouse. 2013, 91, 469-79	28
213	The effect of docosahexaenoic acid on t10, c12-conjugated linoleic acid-induced changes in fatty acid composition of mouse liver, adipose, and muscle. 2013, 11, 63-70	11
212	Fish oil prevents excessive hepatic lipid accumulation without inducing oxidative stress. 2013, 88, 365-71	3
211	Pharmacologic therapy for nonalcoholic fatty liver disease in adults. 2013, 33, 223-42	11
210	Tissue Distribution and Versatile Functions of PPARs. 2013, 33-69	
209	Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. 2013, 13, 85	48
208	Plant-based foods as a source of lipotropes for human nutrition: a survey of in vivo studies. 2013, 53, 535-90	32
207	Management of dyslipidemia in patients with nonalcoholic fatty liver disease. 2013, 98-109	
206	Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. 2013, 39, 214-28	41
205	The expanding role of fish models in understanding non-alcoholic fatty liver disease. 2013, 6, 905-14	63

204	A critical appraisal of advances in pediatric nonalcoholic Fatty liver disease. 2012 , 32, 317-24		17
203	Emerging drugs for non-alcoholic steatohepatitis. 2013 , 18, 279-90		12
202	Steatosis in the liver. 2013 , 3, 1493-532		27
201	Manifestations of fasting-induced fatty liver and rapid recovery from steatosis in voles fed lard or flaxseed oil lipids. <i>Nutrients</i> , 2013 , 5, 4211-30	6.7	7
200	Dietary Factors in the Pathogenesis and Care of Patients with Fatty Liver Disease. 2013 , 248-259		
199	Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). <i>Nutrients</i> , 2013 , 5, 4093-114	6.7	47
198	Current concepts and management approaches in nonalcoholic fatty liver disease. 2013 , 2013, 481893		50
197	Dietary habits and behaviors associated with nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1756-67	5.6	67
196	Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2014 , 9, e88005	3.7	94
195	Non-alcoholic fatty liver disease in children: focus on nutritional interventions. <i>Nutrients</i> , 2014 , 6, 4691-705	6.5	24
194	Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015 , 7, 204-12	3.4	50
193	Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH. 2014 , 12, 741-4		6
192	Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7339-46	5.6	59
191	Non-alcoholic fatty liver disease: what the clinician needs to know. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12956-80	5.6	117
190	Nonalcoholic Fatty Liver Disease (NAFLD), a Manifestation of the Metabolic Syndrome: New Perspectives on the Nutritional Therapy. 2014 , 03,		2
189	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. 2014 , 03,		1
188	Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents. 2014 , 14, e10939		10
187	Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease. 2014 , 16, 255-61		59

186	Systematic review with meta-analysis: meat consumption and the risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 913-22	6.1	41
185	Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. 2014 , 60, 1211-21		210
184	Enhanced amelioration of high-fat diet-induced fatty liver by docosahexaenoic acid and lysine supplementations. 2014 , 2014, 310981		16
183	The role of medications for the management of patients with NAFLD. 2014 , 18, 73-89		24
182	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. 2014 , 46, 632-8		9
181	Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 3-14	6.1	66
180	The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. 2014 , 5, 426-35		61
179	High feeding intensity increases the severity of fatty liver in the American mink (<i>Neovison vison</i>) with potential ameliorating role for long-chain n-3 polyunsaturated fatty acids. 2014 , 56, 5		6
178	Effects of a diet rich in n-3 polyunsaturated fatty acids on hepatic lipogenesis and beta-oxidation in mice. 2014 , 49, 431-44		53
177	Diets and nonalcoholic fatty liver disease: the good and the bad. 2014 , 33, 186-90		110
176	Integrative Weight Management. 2014 ,		2
175	Nonalcoholic Fatty Liver Disease. 2014 , 145-169		1
174	Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. 2014 , 29, 1265-72		64
173	Recent advances in pharmacotherapy for hypertriglyceridemia. 2014 , 56, 47-66		104
172	Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. 2014 , 25, 473-86		28
171	Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition. 2014 , 37, 213-24		8
170	Review article: the management of paediatric nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1155-70	6.1	33
169	No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. 2014 , 147, 377-84.e1		212

168	Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. 2014 , 37, 301-11		39
167	Clinical approaches to non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1713-23		95
166	The Double-Edged Sword of Hepatic Iron Metabolism in Health and Diseases. 2014 , 212-229		
165	Molecular Nutrition The Practical Guide. 2015 ,		
164	Influence of lifestyle habits, nutritional status and insulin resistance in NAFLD. 2012 , 4, 1015-23		1
163	Dietary Patterns Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Chinese Adults. <i>Nutrients</i> , 2015 , 7, 4778-91	6.7	57
162	Assessment of Diet and Physical Activity in Paediatric Non-Alcoholic Fatty Liver Disease Patients: A United Kingdom Case Control Study. <i>Nutrients</i> , 2015 , 7, 9721-33	6.7	18
161	Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. <i>PLoS ONE</i> , 2015 , 10, e0121528	3.7	25
160	Treatment of nonalcoholic steatohepatitis in adults: present and future. 2015 , 2015, 732870		19
159	Role of diet on non-alcoholic fatty liver disease: An updated narrative review. <i>World Journal of Hepatology</i> , 2015 , 7, 575-82	3.4	36
158	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3777-85	5.6	82
157	Dietary rapeseed/canola-oil supplementation reduces serum lipids and liver enzymes and alters postprandial inflammatory responses in adipose tissue compared to olive-oil supplementation in obese men. 2015 , 59, 507-19		50
156	Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. 2015 , 61, 119-28		47
155	Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. 2015 , 49, 1405-18		182
154	Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. 2015 , 7, 121-7		46
153	Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. 2015 , 166, 1358-63.e1-3		80
152	Pros and cons of fatty acids in bone biology. 2015 , 58, 121-45		22
151	Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. 2015 , 99, 25-34		24

150	Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). 2015 , 292-305	1
149	Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. 2015 , 49, 137-44	112
148	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. 2015 , 35, 221-35	235
147	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. 2015 , 35, 338-48	21
146	Non-alcoholic fatty liver disease following liver transplantation: a clinical review. 2015 , 29, 728-37	12
145	Potential for dietary ω 3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. 2015 , 6, 694-702	49
144	Fish, Fish Oil, and Liver Cancer. 2016 , 249-262	
143	BENEFICIOS DE LOS ÁCIDOS GRASOS POLIINSATURADOS DE CADENA LARGA N-3 EN LA ENFERMEDAD POR HÍGADO GRASO NO ALCOHÓLICO. 2016 , 43, 13-13	0
142	Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2016 , 2016, 1459790	52
141	Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. 2016 , 2016, 4597246	32
140	Alcoholic Liver Disease: Update on the Role of Dietary Fat. 2016 , 6, 1	74
139	n-3 polyunsaturated fatty acid supplementation reduces insulin resistance in hepatitis C virus infected patients: a randomised controlled trial. 2016 , 29, 345-53	5
138	Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice. 2016 , 75, 1-9	29
137	How Much Fat Does One Need to Eat to Get a Fatty Liver? A Dietary View of NAFLD. 2016 , 109-122	1
136	Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans. 2016 , 14, 417-430	18
135	Obesity, NASH, and HCC. 2016 , 275-286	
134	[A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis]. 2016 , 136, 583-9	3
133	Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. 2016 , 35, 578-86	65

132	The intersection of nonalcoholic fatty liver disease and obesity. 2016 , 8, 323rv1		43
131	Role of Lipogenesis and Lipid Desaturases in Non-alcoholic Fatty Liver Disease. 2016 , 143-164		
130	Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016 ,		3
129	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. 2016 , 33, 291-319		54
128	Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. 2016 , 20, 351-64		9
127	Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. 2016 , 313-337		
126	Dietary docosahexaenoic acid reverses nonalcoholic steatohepatitis and fibrosis caused by conjugated linoleic acid supplementation in mice. 2016 , 20, 443-452		2
125	Hepatic De Novo Lipogenesis and Regulation of Metabolism. 2016 ,		3
124	Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice. 2016 , 3, 4-14		11
123	Nonalcoholic Fatty Liver Disease. 2016 , 753-774		
122	Nutritional therapy for nonalcoholic fatty liver disease. 2016 , 29, 1-11		72
121	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. 2016 , 53, 106-20		28
120	Ω3 fatty acids as an adjuvant therapy ameliorates methotrexate-induced hepatotoxicity in children and adolescents with acute lymphoblastic leukemia: A randomized placebo-controlled study. <i>Nutrition</i> , 2016 , 32, 41-7	4.8	34
119	Clove bud (<i>Syzygium aromaticum</i>) improved blood and hepatic antioxidant indices in laying hens receiving low n-6 to n-3 ratios. 2017 , 101, 881-892		5
118	Predictive value of serum dihomo-Δ ⁵ -linolenic acid level and estimated Δ ⁵ desaturase activity in patients with hepatic steatosis. 2017 , 11, 34-43		15
117	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. 2017 , 83, 88-95		54
116	Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease. 2017 , 67, 1-13		12
115	Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease. 2017 , 174, 2358-2372		32

114	Non-alcoholic fatty liver disease: A sign of systemic disease. 2017 , 72, 94-108		92
113	Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster. 2017 , 135, 1-11		5
112	Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima-media thickness: a pilot study. 2017 , 3, 201-211		3
111	Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy. 2017 , 266, 324-332		10
110	Effect of oregano essential oil supplementation to a reduced-protein, amino acid-supplemented diet on meat quality, fatty acid composition, and oxidative stability of Longissimus thoracis muscle in growing-finishing pigs. 2017 , 133, 103-109		34
109	Effect of a Low Glycemic Index Mediterranean Diet on Non-Alcoholic Fatty Liver Disease. A Randomized Controlled Clinical Trial. 2017 , 21, 404-412		60
108	Malnutrition and Liver Disease. 2017 , 460-487		0
107	Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2017 , 9,	6.7	54
106	Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper. <i>Nutrients</i> , 2017 , 9,	6.7	31
105	Dietary factors can protect against liver cancer development. <i>World Journal of Hepatology</i> , 2017 , 9, 119-125	3.25	28
104	Pretreatment with intravenous fish oil reduces hepatic ischemia reperfusion injury in a murine model. 2018 , 163, 1035-1039		4
103	A Khorasan Wheat-Based Replacement Diet Improves Risk Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized Clinical Trial. 2018 , 37, 508-514		14
102	Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. 2018 , 58, 28-36		21
101	Association of processed food, synergistic effect of alcohol and HBV with Hepatocellular Carcinoma in a high incidence region of India. 2018 , 53, 35-41		6
100	The potential role of statins in treating liver disease. 2018 , 12, 331-339		10
99	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. 2018 , 64, 135-146		61
98	Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials. 2018 , 37, 113-122		35
97	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. 2018 , 37, 37-55		66

96	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. 2018 , 181, 108-125	64
95	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. 2018 , 67, 328-357	2641
94	Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. 2018 , 22, 175-187	21
93	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2018 , 22, 189-199	19
92	Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology. 2018 , 52, 92-102	28
91	Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight. 2018 , 37, 1474-1484	37
90	Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120). 2018 , 1863, 105-116	27
89	Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. 2018 , 97, e12271	55
88	Dietary Genistein Alleviates Lipid Metabolism Disorder and Inflammatory Response in Laying Hens With Fatty Liver Syndrome. 2018 , 9, 1493	27
87	Effective Food Ingredients for Fatty Liver: Soy Protein β -Conglycinin and Fish Oil. 2018 , 19,	8
86	Judicious Use of Lipid Lowering Agents in the Management of NAFLD. 2018 , 6,	7
85	Mechanisms by Which Dietary Fatty Acids Regulate Mitochondrial Structure-Function in Health and Disease. 2018 , 9, 247-262	37
84	Betaine Supplementation Enhances Lipid Metabolism and Improves Insulin Resistance in Mice Fed a High-Fat Diet. <i>Nutrients</i> , 2018 , 10,	6.7 45
83	Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN). <i>Nutrients</i> , 2018 , 10,	6.7 15
82	Impact of diet on irinotecan toxicity in mice. 2018 , 291, 87-94	8
81	Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. 2018 , 76, 581-602	49
80	Non-invasive assessment of hepatic lipid subspecies matched with non-alcoholic fatty liver disease phenotype. 2019 , 29, 1197-1204	10
79	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. 2019 , 9, 497-505	11

78	Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and men. 2019 , 48, 1863-1871		19
77	Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease. <i>Nutrition</i> , 2019 , 62, 100-107	4.8	15
76	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99		15
75	The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH). 2019 , 10, 770		16
74	Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. <i>Nutrients</i> , 2019 , 11,	6.7	88
73	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2019 , 11,	6.7	71
72	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99		1
71	Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. <i>Nutrients</i> , 2019 , 11,	6.7	28
70	Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation. 2019 , 373-389		2
69	Effects of dietary apple polyphenol supplementation on carcass traits, meat quality, muscle amino acid and fatty acid composition in finishing pigs. 2019 , 10, 7426-7434		19
68	The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF- κ B and TGF β pathways in hepatic stellate cells. 2019 , 10, 14		19
67	Lipidomic analysis reveals the efficiency of <i>Eclipta prostrata</i> on diet-induced nonalcoholic fatty liver disease in rats. 2019 , 165, 224-232		6
66	The influence of dietary fatty acids on liver fat content and metabolism. 2020 , 79, 30-41		22
65	Erythrocyte membrane n-3 polyunsaturated fatty acids are inversely associated with the presence and progression of nonalcoholic fatty liver disease in Chinese adults: a prospective study. 2020 , 59, 941-951		1
64	Nutrition and Nonalcoholic Fatty Liver Disease: Current Perspectives. 2020 , 49, 63-94		26
63	Addition of fish oil to atherogenic high fat diet inhibited atherogenesis while olive oil did not, in LDL receptor KO mice. 2020 , 30, 709-716		4
62	Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men-A Randomized Controlled Trial. 2020 , 64, e2000419		7
61	Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial. <i>Nutrients</i> , 2020 , 12,	6.7	6

60	The Effects of Nuts on Metabolic Diseases and Disorders. 2020 , 291-298		
59	Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH. <i>Nutrition</i> , 2020 , 75-76, 110782	4.8	12
58	Association of the dietary patterns with the risk of non-alcoholic fatty liver disease among Iranian population: a case-control study. 2020 , 19, 63		3
57	Diet and liver cancer risk: a narrative review of epidemiological evidence. 2020 , 124, 330-340		32
56	Addressing the heterogeneity in liver diseases using biological networks. 2021 , 22, 1751-1766		6
55	The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. 2021 , 697, 108679		6
54	Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial. 2021 , 36, 1953-1961		5
53	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. 2021 , 6, 60		2
52	Nutraceuticals for Non-alcoholic Fatty Liver Disease. 2021 , 141-165		
51	The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. 2021 , 50, 217-241		2
50	Food and Nutrition in the Pathogenesis of Liver Damage. <i>Nutrients</i> , 2021 , 13,	6.7	3
49	Effects of slaughter age on carcass traits and meat quality of crossbred (Duroc × Landrace × Yorkshire) finishing pigs. 2021 , 1-7		2
48	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation. 2021 , 22,		2
47	Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: A randomized controlled trial. <i>Clinical Nutrition ESPEN</i> , 2021 , 44, 130-135	1.3	6
46	Effects of trans-anethole supplementation on serum lipid metabolism parameters, carcass characteristics, meat quality, fatty acid, and amino acid profiles of breast muscle in broiler chickens. <i>Poultry Science</i> , 2021 , 100, 101484	3.9	1
45	N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune-Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses. <i>Nutrients</i> , 2021 , 13,	6.7	0
44	Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes. 2013 , 61-73		1
43	Nutritional And Clinical Strategies On Prevention And Treatment Of Nafld And Metabolic Syndrome. 2009 , 113-130		1

42	Emerging Nutritional Treatments For Nonalcoholic Fatty Liver Disease. 2009 , 131-146		1
41	Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2016 , 11, e0162368	3.7	57
40	Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. <i>Journal of Clinical and Translational Hepatology</i> , 2015 , 3, 78-84	5.2	59
39	Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. <i>Current Medicinal Chemistry</i> , 2020 , 27, 5250-5272	4.3	26
38	Short Term Usage of Omega-3 Polyunsaturated Fatty Acids Ameliorate Lipopolysaccharide-Induced Inflammatory Response and Oxidative Stress in the Neonatal Rat Hippocampal Tissue. <i>Frontiers in Nutrition</i> , 2020 , 7, 572363	6.2	1
37	Associations between Dietary Nutrient Intakes and Hepatic Lipid Contents in NAFLD Patients Quantified by ¹ H-MRS and Dual-Echo MRI. <i>Nutrients</i> , 2016 , 8,	6.7	28
36	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. <i>Advanced Pharmaceutical Bulletin</i> , 2020 , 10, 542-555	4.5	3
35	Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2008 , 14, 22-8	5.6	120
34	Olive oil consumption and non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 1809-15	5.6	102
33	Strategies to rescue steatotic livers before transplantation in clinical and experimental studies. <i>World Journal of Gastroenterology</i> , 2013 , 19, 4638-50	5.6	16
32	Role of diet and lifestyle changes in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9338-44	5.6	75
31	Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14219-29	5.6	29
30	Recent advances in liver preconditioning: Thyroid hormone, n-3 long-chain polyunsaturated fatty acids and iron. <i>World Journal of Hepatology</i> , 2012 , 4, 119-28	3.4	25
29	Lipid-lowering agents in the management of nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014 , 6, 738-44	3.4	12
28	Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014 , 6, 800-11	3.4	52
27	Using Parenteral Fish Oil In Nash. 2009 , 81-95		
26	Insulin Resistance and Non-alcoholic Fatty Liver Disease Induced by Conjugated Linoleic Acid in Humans. 2010 , 133-147		
25	Circulatory Injury in Liver Transplantation. 2011 , 65-75		

24	La stéato-hépatite non alcoolique. Influence de la nutrition, de la physiopathologie au traitement. 2011 , 35-46		
23	Patología de hígado graso no-alcohólico (HGNA) asociada a obesidad: mecanismos patogénicos. <i>Medwave</i> , 2011 , 11,	2.5	
22	Association of Serum CK18 M30 Antigen Level with Food Intake in Middle-aged Japanese Men. <i>Nihon Eiyōshokuryōgakkai Shi = Nippon Eiyōshokuryōgakkai Shi = Journal of Japanese Society of Nutrition and Food Science</i> , 2014 , 67, 127-135	0.2	
21	Effects of Dietary Fish Oil on the Oxidative Stress in Obese Zucker Rats. <i>Japanese Journal of Complementary and Alternative Medicine</i> , 2016 , 13, 13-19	0	1
20	7. The role of diet in systemic and neural inflammation in obesity and metabolic syndrome. <i>Human Health Handbooks</i> , 2017 , 131-166		
19	Non-Alcoholic Fatty Liver Disease, an Overview. <i>Integrative Medicine</i> , 2019 , 18, 42-49	0.4	8
18	Serum concentration of fatty acids in children with obesity and nonalcoholic fatty liver disease.. <i>Nutrition</i> , 2021 , 94, 111541	4.8	0
17	Nonalcoholic Fatty Liver Disease. 2022 , 911-930		
16	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. <i>World Journal of Hepatology</i> , 2022 , 14, 119-139	3.4	4
15	Quelle alimentation proposer aux patients présentant une stéatohépatite non-alcoolique?. <i>Nutrition Clinique Et Metabolisme</i> , 2022 , 36, 12-20	0.8	0
14	Anti-Inflammatory Dietary Approach to Prevent the Development and Progression of Non-Alcoholic Fatty Liver Diseases. <i>Livers</i> , 2022 , 2, 78-84		0
13	Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial.. <i>BMC Nutrition</i> , 2021 , 7, 86	2.5	0
12	Data_Sheet_1.docx. 2019 ,		
11	Data_Sheet_2.pdf. 2019 ,		
10	Lipids and nonalcoholic fatty liver disease. 2022 , 135-146		
9	Associations of serum n-3 and n-6 polyunsaturated fatty acids with prevalence and incidence of non-alcoholic fatty liver disease. <i>American Journal of Clinical Nutrition</i> ,	7	2
8	Nonalcoholic Fatty Liver Disease. <i>In Clinical Practice</i> , 2022 , 163-184	0	
7	Unified approach to optimal estimation of mean and standard deviation from sample summaries. <i>Statistical Methods in Medical Research</i> , 096228022211115	2.3	2

6	Evidence-based management of patients with nonalcoholic fatty liver disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022 , Published Ahead of Print,	0.8	○
5	Differential Effects of Dietary White Meat and Red Meat on NAFLD Progression by Modulating Gut Microbiota and Metabolites in Rats. 2022 , 2022, 1-19		○
4	Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. 2023 , 15, 23		2
3	Lipid Disorders and Metabolic-Associated Fatty Liver Disease. 2023 ,		○
2	The diverse roles of macrophages in metabolic inflammation and its resolution. 11,		○
1	Nutritional and Lifestyle Therapy for NAFLD in People with HIV. 2023 , 15, 1990		○